Mounjaro and Zepbound brought in $14.9B in Q2 2026, though realized prices fell 13%. The bull case leans on retatrutide and Foundayo.
Recap by typeshit. Full story at 24/7 Wall St..
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
New research points to a possible link between GLP-1 medications and changes in nails, and doctors weigh in on what so-called Ozempic nails could mean.
A generic social post comparing the two drugs for weight loss and pointing to the head-to-head SURMOUNT-5 results. Nothing new beyond the trial itself.
Loading…